Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with ...

Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Reports Q4 revenue $2.074B, consensus $2.05B. “Solventum (SOLV) executed another quarter of solid performance, enabling us to deliver full year ...

M health care spinoff Solventum is selling its purification business to Thermo Fisher Scientific for $4.1 billion in cash to ...

The Maplewood, Minnesota-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, were $1.41 per share. The results topped Wall Street expectations.

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...

Thermo Fisher’s release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business’ current ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...

ST. PAUL, Minn. - Solventum Corporation (NYSE: SOLV) reported fourth-quarter earnings that fell short of analyst expectations, sending shares down 2% in after-hours trading. The healthcare technology ...

Solventum Corp. closed 20.58% short of its 52-week high of $96.05, which the company achieved on March 26th.